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Background: A high fat calorie diet is advocated for patients with cystic fibrosis (CF) however the lipid profiles of individuals with CF, including
those with CF-related diabetes (CFRD), are not well studied.
Methods: We conducted a retrospective review of adult CF patients attending St Michael's Hospital between January 2005 and December 2007.
Results: 334 patients (77% pancreatic insufficient (PI)) were included in the study. Mean HDL cholesterol was significantly lower in males
(pb0.0001) with 44% of males having HDL cholesterol b38.7 mg/dL(1 mmol/L). Pancreatic sufficient patients were more likely than PI subjects
to have total cholesterol N201 mg/dL(5.2 mmol/L) (pb0.01). 5% of subjects had triglyceride concentrations N195 mg/dL(2.2 mmol/L). Diabetes
was diagnosed in 23% of subjects. Lipid profiles were similar between diabetics and non-diabetics. Total cholesterol and triglycerides both
increased with increasing age and increasing BMI (pb0.01).
Conclusion: Dyslipidemia occurs in CF patients however no differences in lipid profiles were seen between those with diabetes and those without.
Fasting lipids should be monitored in CF patients, particularly those with PS, older age, and high BMI. As survival in CF increases, the prevalence
of dyslipidemia may increase resulting in clinically important complications.
© 2009 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Cystic fibrosis; Diabetes; Lipids1. Introduction
The life expectancy of patients with cystic fibrosis (CF) has
improved dramaticallywithmedian survival now over 37 years of
age [1]. A high fat, high calorie diet is a long-established and
integral part of CF management, particularly for pancreatic
insufficient (PI) patients. This dietary regimen, in associationwith
pancreatic enzyme supplementation, helps satisfy the dietary
requirements of CF patients. However, it has been shown that
even with enzyme supplementation, fat and fat-soluble vitamins
are still malabsorbed [2]. It has previously been reported that CF☆ Data from this manuscript was presented at the North American Cystic
Fibrosis Conference, October 2008, Orlando, Florida, USA.
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doi:10.1016/j.jcf.2009.09.002patients have lower total cholesterol than the non-CF population
despite their diet [3,4]. This is presumed to be secondary to
decreased exogenous lipid absorption, however the effects of a
high fat diet on overall lipid profiles in the adult CF population is
not known. In the non-CF population, a high fat diet is associated
with the development of dyslipidemia, which is a well-recognized
risk factor for atherosclerotic disease [5]. The prevalence of
ischemic heart disease in the CF population is reported to be lower
than the general population [6]. A high fat, high calorie diet was
first introduced in the Toronto CF clinic in the early 1970s [7]
therefore many patients have now lived with this diet for over
40 years. As life expectancy for those with CF continues to
improve, the repercussions of this diet on parameters other than
nutritional markers and vitamin status need to be examined.
Also related to improved life expectancy of CF patients, CF-
related diabetes (CFRD) has become a more frequent long-termd by Elsevier B.V. All rights reserved.
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fasting hyperglycemia) is associated with advancing age,
affecting 35% of adults in their twenties and 43% of adults over
the age of 30 [8]. Insulin resistance in the general population is
associated with dyslipidemia, with the most common pattern
being hypertriglyceridemia, low HDL cholesterol and normal
LDL cholesterol [9], however the effect of CFRD on lipids is
unclear. CFRD differs from both type I and type II diabetes in that
it is a combination of insulin deficiency, as well as peripheral and
hepatic insulin resistance [8,10]. Microvascular complications are
well described in CFRD and appear to be related to time with the
disease and diabetic control [11]. The lack of published literature
on macrovascular complications has been hypothesized to be, a
least in part, related to the presumed favorable lipid profile in CF,
however the shorter life span may also be limiting this potential
longer-term complication.
In this study we aim to characterize lipid profiles in a large
cohort of adult CF patients and to identify potential subgroups
at increased risk for dyslipidemia [12].
2. Subjects and methods
We conducted a retrospective cross-sectional review of adult
CF patients attending St Michael's Hospital between January
2005 and December 2007. Relevant data had been prospec-
tively entered into the Toronto CF database during this period.
All patients in whom a fasting lipid profile was measured during
this period were included. If patients underwent double lung
transplantation, subsequent lipid results were excluded from
analysis. All included patients fulfilled the CF Foundation
consensus criteria for the diagnosis of CF [13]. Patients
provided informed written consent for their data to be submitted
to the Toronto CF Patient Data Registry. The Research Ethics
Board at St. Michael's Hospital approved the study.
2.1. Predictor variables
Age, gender, BMI, forced expiratory volume in 1second
(FEV1), CFRD status and pancreatic status were documented
for all patients on the same day that the lipid measurements were
carried out. FEV1 percent predicted was calculated using the
Hankinson equation [14]. Pancreatic status was determined by
reviewing pancreatic enzyme usage, previous trypsinogen
levels and fecal fat collection results.
Oral glucose tolerance tests (OGTT) were performed yearly on
all CF patients without a diagnosis of CFRD. CFRD was defined
as persistently elevated blood sugars and/or positive OGTT in a
stable state of health where the final outcome was initiation of
medical treatment for diabetes. OGTT was performed according
to the 1999 Consensus Conference Report on CFRD [15]. The
fasting plasma glucose (FPG) and 2-h plasma glucose (2hPG)was
measured after an oral glucose load of 1.75 g/kg body weight
(maximum 75 g). Patients were classified into glucose tolerance
categories according to the OGTT results: normal glucose
tolerance (NGT) if FPGb126 mg/dL (7.0 mmol/L) and 2hPG
below 141 mg/dL (7.8 mmol/L); impaired glucose tolerance
(IGT) if FPGb126 mg/dL (7.0 mmol/L) and 2hPG between 141and 200 mg/dL (7.8 and 11.1 mmol/L); CFRD without fasting
hyperglycemia (FH) if FPGb126 mg/dL (7.0 mmol/L) and
2hPGN200 mg/dL (11.1 mmol/L); and CFRD with FH if
FPG N126 mg/dL (7.0 mmol/L) and 2hPG N200 mg/dL
(11.1 mmol/L). In general, patients with IGT or CFRD with and
without FH on an OGTT went on to have home glucose moni-
toring. Those with persistently elevated blood sugars proceeded
to treatment at the discretion of the treating physician. Most
individuals who started treatment had CFRD with FH. The ma-
jority of CFRD patients commenced insulin therapy however a
small number were treated with oral hypoglycemic medications.
2.2. Outcome variable
Fasting lipid profiles were carried out annually as part of
routine care. If subjects had more than 1 lipid profile done
within the study time period, the lipid profile containing the
most complete lipid parameters was chosen for the study. Lipid
analysis was performed with either the Beckman Coulter Unicel
DxC 600 or the Beckman Couler LX20 analyzer. Cholesterol
and triglycerides were analyzed using enzymatic methods. LDL
cholesterol was calculated using the Friedewald equation [16].
Hyperlipidemia cut-off points were determined using recom-
mendations from the National Cholesterol Education Program
[17] and Canadian Recommendations for the Management of
Dyslipidemia 2003 [18]. The Canadian recommendations use
the total/HDL cholesterol ratio as well as LDL cholesterol to
provide target lipid ranges dependent on cardiovascular (CV)
risk. The total/HDL cholesterol ratio has a greater predictive
value for CV risk than individual lipid parameters alone in the
general population, with a ratio of b4.0 recommended for those
at high risk of coronary artery disease or those with a history of
diabetes.
2.3. Statistics
Descriptive statistics for continuous variables are given as
means±standard deviations (SD) unless otherwise indicated.
Categorical variables were analyzed using Fischer's exact test.
Student's t test was used to compare mean values between 2
groups for continuous variables. Parametric and non-parametric
testing was carried out to ensure consistent results. p-values of
b0.05 are reported as significant in the results. Statistical
analysis was performed with SAS software (version 9.1; SAS
Institute Inc, Cary, NC).
3. Results
Baseline descriptive characteristics of the subjects are given in
Table 1. Out of the 334 subjects with fasting lipid profiles, 328
(98%) had total cholesterol (TC) results, 326 (98%) had
triglyceride results and 170 (51%) had HDL cholesterol, LDL
cholesterol and Total/HDL cholesterol ratio results. The included
subjects represented 90% of our clinic population. Males and
females had similar demographics except that females had lower
BMI (21.6±3.6 vs. 23.0±3.7 kg/m2, pb0.01). Lipid results
according to gender are shown in Table 2. The majority of mean
Table 1
Baseline characteristics for subjects (n=334).
Variables Result
Age (years) 31±10
FEV1 (% predicted) 59±22
Gender (% male) 59
BMI (kg/m2) 22.4±4
CFRD (%) 23
PI (%) 77
Values are mean±SD unless otherwise stated.
Table 3
Percentage of subjects with elevated lipid values, by pancreatic status.
Variable (mmol/L) PI PS p-value
Total cholesterolN201 (% subjects) 4 20 b0.01
TriglyceridesN150 (% subjects) 14 18 0.4
LDL cholesterolN97 (% subjects) 14 57 b0.01
HDL cholesterolb38.7 (% subjects) 52 41 0.3
Total/HDL cholesterolN4 a (% subjects) 24 43 0.03
To convert mg/dL to mmol/L for TC, HDL, LDL multiply by 0.0259; for TG
multiply by 0.0113.
a Ratio has no units.
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as suggested by national guidelines. The notable exception was
mean HDL cholesterol for males, which was below the
recommended target minimum of 38.7 mg/dL (1 mmol/L) and
significantly lower than females (37.5±10.8 mg/dL (0.97±
0.28 mmol/L) vs. 46.8 ±14.7 mg/dL (1.21±0.38 mmol/L),
pb0.01). Furthermore, a significantly greater proportion of
males compared to females had HDL cholesterol b38.7 mg/dL
(1 mmol/L) (44% vs. 23% respectively, p=0.004).
3.1. Pancreatic status and lipids
Subjects were categorized by pancreatic status with 77% being
PI. PS subjects were significantly older than PI subjects (38.2±
11.9 vs. 29.2±8.8 years, pb0.0001) with higher BMI (24.7±4.5
vs. 21.7±3.1 kg/m2, pb0.0001). PI subjects had significantly
lower TC (138±34 vs. 172±36 mg/dL (3.56±0.87 vs. 4.45±
0.94 mmol/L), pb0.0001) and LDL cholesterol (74±21 vs. 104±
27 mg/dL (1.91±0.55 vs. 2.68±0.71 mmol/L), pb0.0001)
compared with PS subjects. HDL cholesterol was slightly lower
in PI patients (40±12 vs. 46±16 mg/dL (1.04±0.32 vs. 1.19±
0.41 mmol/L), p=0.04) but total/HDL cholesterol ratio was also
significantly lower than PS patients (3.52±0.98 vs. 4.02±1.06,
p=0.02). A significantly higher percentage of PS subjects was
found to have TC, LDL cholesterol, and total/HDL cholesterol
above the optimal target range compared to PI patients (Table 3).
Twenty percent of PS patients had TCN201 mg/dL (5.2 mmol/L)
and 57% had LDL cholesterol N97 mg/dL (2.5 mmol/L).
Notably, some PI subjects also had elevated lipid profiles, albeit
in smaller numbers than PS patients. Despite the age difference
between the 2 groups, TC, LDL cholesterol and total/HDL
cholesterol results remained significantly different between the PI
and PS subjects after correcting for sex and age.Table 2
Gender differences in lipid profiles.
Variable (mg/dL) Female Male p-value
Total cholesterol 154±37.5 140±36 b0.01
Triglyceride 97±56 95±57 0.8
HDL cholesterol 47±15 37±11 b0.0001
LDL cholesterol 83±26 80±26 0.4
Total/HDL cholesterol a 3.39±0.96 3.85±1.12 0.004
To convert mg/dL to mmol/L for TC, HDL, LDL multiply by 0.0259; for TG
multiply by 0.0113.
Values are mean±SD unless otherwise stated.
a Ratio has no units.3.2. CFRD and lipids
There were 77 (23%) subjects with CFRD. This group was
compared to the PI patient group without CFRD (n=181). PS
subjects were excluded from this analysis as no PS subjects had
CFRD. CFRD subjects were older (32±10 vs. 28±8 years, p=
0.005) with lower mean FEV1% predicted (50±23 vs. 58±20 %,
p=0.01) but similar BMI. No statistically significant difference
was found in lipid profiles between CFRD and non-CFRD PI
patients and the proportion of subjects with lipid levels above
optimal targets did not differ between the two groups (Table 4).
3.3. BMI, age and lipids
TC and total /HDL cholesterol ratio all increased with
increasing BMI (pb0.001) and this trend remained significant
(p=0.01) after excluding PS subjects. On subgroup analysis of
male PI subjects, we found the higher the BMI the more likely
they were to have a total/HDL cholesterol ratio N4 (p=0.01).
Fifteen male PI subjects with a BMIN26 kg/m2 had total/HDL
cholesterol tested and 8 of these subjects (53.3%) had a ratio
N4 compared to 14.0% (6/43 subjects) of those with a BMIb
22 kg/m2. In all subjects, and after excluding PS patients, TC
and LDL cholesterol levels increased with increasing age (both
pb0.01).
3.4. Triglycerides
Sixteen percent of all subjects had triglycerides N150 mg/
dL (1.7 mmol/L) and 5% had triglycerides N195 mg/dL
(2.2 mmol/L). Triglycerides were not significantly higher inTable 4
Percentage of pancreatic insufficient subjects with elevated lipid values, by
CFRD status.
Variable (mmol/L) CFRD Non-CFRD p-value
Total cholesterolN201 (% subjects) 5 4 0.7
TriglyceridesN150 (% subjects) 19 12 0.2
LDL cholesterolN97 (% subjects) 20 11 0.2
HDL cholesterolb38.7 (% subjects) 57 49 0.5
Total/HDL-CN4 a (% subjects) 24 23 0.8
To convert mg/dL to mmol/L for TC, HDL, LDL multiply by 0.0259; for TG
multiply by 0.0113.
a Ratio has no units.
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increasing age (pb0.008) and increasing BMI (p b 0.0001).
Male PI subjects with higher BMI were more likely to have
triglycerides N150 mg/dL (1.7 mmol/L) compared to those
with lower BMI (pb0.01). Of the 26 male PI subjects with a
BMIN26 kg/m2, 9 subjects (34.6%) had an elevated triglyc-
eride concentration compared to only 9.7% of those with a
BMI of 19–22 kg/m2. None of the 24 male PI subjects with a
BMIb19 had elevated triglycerides.
4. Discussion
This study examines the lipid profile of a large cohort of adults
with CF and evaluates the association between lipid abnormalities
and pancreatic and CFRD status. We found that PS subjects were
more likely to develop dyslipidemia compared to PI subjects,
specifically elevated TC, LDL cholesterol and total/HDL
cholesterol. In PI subjects, TC, LDL and HDL cholesterol tended
to be lower, however in 24% of subjects total/HDL cholesterol
was N4. Increasing age and BMI were associated with elevated
total/HDL cholesterol ratios in PI subjects. There were no
differences in lipid profiles between those with CFRD and those
without, even once PS subjects were excluded.
Previous investigators have reported lower serum TC concen-
trations in the CF patient population compared to the general
population [3,4]. Figuero et al. reported a high prevalence of
hypertriglyceridemia in their CF clinic population, with 16% of
patients having triglycerides N195 mg/dL (2.2 mmol/L) [3]. In
the current study 16% of subjects had triglycerides N150 mg/dL
(1.7 mmol/L), but only 5% of subjects had triglycerides
N195 mg/dL (2.2 mmol/L). The reason for this difference in
prevalence of hypertriglyceridemia between these patient popu-
lations is unclear. The study population in the Figuero study
included children as well as adults and had higher FEV1 than our
patient population. However, they found no correlation between
age or lung function in their study, suggesting that these factors
are not an adequate explanation for the observed differences in
prevalence of hypertriglyceridemia.
4.1. Association between gender and lipid profiles
Male subjects had lower HDL cholesterol compared to
females in the current study. The gender difference with HDL
cholesterol may be explained, at least partially, by the actions of
estrogen. Estrogens are known to have profound effects on
cholesterol metabolism in the non-CF population [19,20].
Estrogens increase HDL cholesterol by augmenting the
secretion of apoA-I and also reduces HDL breakdown by
reducing hepatic lipase activity [21]. HDL cholesterol has also
been shown to have other properties including immune system
regulation, anti-inflammatory, antioxidant, antithrombotic and
antivasospastic effects [22]. ApoA-1 and apoA-2 are the major
apolipoproteins of HDL cholesterol with higher ApoA-1
protective against CV disease [23]. Given the low incidence
of cardiovascular disease in the CF population despite low HDL
cholesterol, further investigation of apoplipoproteins levels in
CF may prove of interest.4.2. Potential explanations for dyslipidemia in CF
Lower lipid values seen in PI subjects in the current study
could be explained by decreased exogenous lipid absorption. PI
patients are known to malabsorb dietary fat despite adequate
intake of pancreatic enzymes [2]. This is due to either incomplete
intraluminal solubilization or reduced intestinal mucosal uptake
of long-chain fatty acids [2]. Furthermore, chronic inflammation
seen in CF may play a role in dyslipidemia [3]. Pro-inflammatory
cytokines such as TNF-∝ are elevated in CF and are known to
inhibit lipoprotein lipase activity and stimulate hepatic lipogen-
esis [24]. Levy et al. [4] showed a strong positive correlation
between serumTNF-∝ and plasma triglycerides in CF adolescent
patients. An alternate explanation for abnormal serum lipids in CF
is dysfunction of the CF transmembrane conductance regulator
(CFTR). Tissues deficient in CFTR have altered levels of fatty
acids, with an increased ratio of arachidonic acid to docosahex-
aenoic acid. In addition, cultured epithelial cells from animal CF
models show abnormal intracellular accumulations of unester-
ified cholesterol [25].White et al. also reported increased levels of
plasma membrane cholesterol and abnormal intracellular choles-
terol trafficking in an in vitro CF cell model. Abnormalities in
fatty acid profiles are seen in vivo in both PI and PS CF patients,
but also in heterozygote parents of CF patients [26]. These
findings suggest that mutations in CFTR may directly alter fatty
acid metabolism.
The significant differences in lipid concentrations comparing
PI and PS patients seen in the current study suggest that these
differences could at least partly be explained by impaired lipid
absorption. Prospective studies are required to confirm this
suggestion and evaluate the contribution of the other potential
mechanisms discussed.
4.3. Relevance of dyslipidemia with regards to cardiovascular
risk in CF adults
In the non-CF population, low HDL and elevated total/HDL
cholesterol ratio are independent predictors of cardiovascular
disease [27]. However CF patients, despite their high fat, high
calorie diet and high prevalence of CFRD, are yet to demonstrate
an increased cardiovascular risk during their lifetime. Microvas-
cular disease is seen in patients with CFRD, although to a lesser
degree than in the non-CF diabetic population [11]. There have
been individual case reports of CF adults with ischemic heart
disease, but these reports are infrequent [6].
This apparent lack of significant atherosclerotic disease
could be explained the low proportion of patients who survive
into their fifth and sixth decades, when the incidence of
cardiovascular disease is at its peak in the non-CF population.
Another potential explanation is the finding by previous
investigators that the majority of patients have normal or
below normal levels of serum total cholesterol [3]. Indeed we
have confirmed in the current study that the majority of PI
patients have favorable lipid profiles. However, we have
demonstrated that a considerable proportion of PS patients
have elevated total cholesterol and total/HDL cholesterol ratios,
which may increase their lifetime cardiovascular risk. It should
28 B. Rhodes et al. / Journal of Cystic Fibrosis 9 (2010) 24–28be mentioned that the proportion of CF patients who are PS may
increase as more patients with milder disease are detected by
newborn screening. In addition, CF infants born in the year
2000 are projected to have median survival of 50 years [28]. CF
adults may therefore have higher prevalence of cardiovascular
disease over coming decades.
4.4. Limitations
The retrospective study design limits the conclusions;
however, the large sample size includes a wide range of disease
severity increasing the generalizability of the results. Only 51%
of our study population had HDL and LDL cholesterol levels
measured, although this population did not differ in character-
istics from the overall study group. Medications that could
interfere with lipid profiles were not recorded for the study.
However, less than 1% of our patients take prescription lipid-
lowering therapy therefore it is unlikely that this affected the
results. An important limitation in detecting the effect of CFRD
on lipids relates to our definition of CFRD. Our definition
provided a diagnostic cut-off point between CFRD and non-
CFRD whereas blood sugar control in CF is more a fluctuating
spectrum of degrees of glucose intolerance. Patients labeled as
non-CFRD may have had a degree of glucose intolerance not
captured with the present study. Furthermore, lipid profiles in
CFRD patients may indeed be different than their non-CFRD
counterparts but this may have been obscured by not taking into
consideration the duration of disease.
4.5. Conclusions
Management of dyslipidemia in the CF population requires a
different approach to the non-CF population, since a life-long
high fat, high calorie diet is recommended. As prognosis of CF
patients improves, the median age of the patient population will
increase. We expect that this will result in higher prevalence of
dyslipidemia in the CF patient population, which may translate
into higher prevalence of cardiovascular disease. If this is the
case, assessment and treatment of dyslipidemia, combined with
monitoring of other cardiovascular risk factors, will become
more relevant over the coming decades.
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